Industry exec Jimenez hopes President Trump’s reform proposals, expected in next three months, will include measures to ensure manufacturer rebates are passed through to patients and encourage outcomes-based reimbursement contracts with payers.
Novartis AG CEO Joseph Jimenez is hopeful that supply chain reforms aimed at ensuring drug manufacturer discounts are passed through to end users will be part of the Trump Administration’s forthcoming drug pricing proposals.
During the company’s investor day May 31, Jimenez said he expects the administration will come out with a set of...
The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.
Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.
A new plan to tackle medicine shortages proposes to develop a set of incentives for companies to manufacture essential medicines in Spain.
Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.
China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.
